Qualitative PCR-based detection of genetically modified soy and maize products in Iran

Soy and maize are the most cultivated genetically modified (GM) crops in the world, which are commonly used in many food products. Establishing regulations for food products containing transgenic materials are obligatory in many countries in order to provide consumers with information. For this purpose, an accurate qualitative polymerase chain reaction (PCR) method was applied to investigate GM food products from Iran. In present study, a total of 90 non-labeled soy and maize samples were collected from Tehran�s market and their DNA were extracted by a kit. All samples were analyzed to screen the 35 S promoter and (nopaline synthase) NOS terminator elements. Having screened the GM positive samples, they were subjected to identification of specific transgenic events RR soy, Bt11 and MON810 maize with PCR. According to our results, 95 of soy and 60 of maize analyzed samples were positive for the 35 S promoter and NOS terminator. Furthermore, event-specific analysis indicated the presence of RR soy, Bt11 and MON810 maize in tested samples, while none of these food-derived samples demonstrated any GM label. The obtained results revealed that the necessity of monitoring system to provide a good reliable control of GM materials in food products and subsequently on their labeling. © 2020, © 2020 Payam Safaei, Sassan Rezaie, Mahmood Alimohammadi, Setareh Agha Kuchak Afshari, Mehrangiz Mehdizadeh and Ebrahim Molaee Aghaee. Published with license by Taylor & Francis Group, LLC

Comparative in vitro activities of seven antifungal drugs against clinical isolates of Candida parapsilosis complex

Objective: Candida parapsilosis species complex, an important set of non-albicans Candida species, is known to cause candidaemia particularly in neonates and infants. However, the incidence has increased in recent years, owing to higher numbers of at individuals at risk for these infections. Our objective was to evaluate the in vitro susceptibility of clinical isolates of C. parapsilosis complex isolates from Iran to seven antifungal drugs. Material and methods: One hundred-one clinical isolates of C. parapsilosis species complex cultured from humans were included. Species identification had been previously confirmed by combined phenotypic characteristics, matrix-assisted laser desorption ionization-time of flight mass spectrometry-based assay and reconfirmed by DNA sequence analysis of the ITS rDNA region and D1/D2 gene. Minimum inhibitory concentrations (MICs) for amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, micafungin and anidulafungin were determined against well-characterized isolates by broth microdilution susceptibility testing according to the CLSI M27-A3 guideline. Results: Species identifications were performed on 101 isolates, of which 88 (87.2) C. parapsilosis sensu stricto and 13 (12.8) C. orthopsilosis. Amphotericin B and posaconazole were the most active drugs with 100 of isolates being wild-type (WT). Voriconazole and micafungin, 99 of isolates were WT. The low activity was recorded for fluconazole and itraconazole with 93.1 and 89.1 of isolates being WT, respectively. At the species level, all Candida parapsilosis sensu stricto isolates were WT to amphotericin B and posaconazole and all Candida orthopsilosis isolates were WT to amphotericin B, voriconazole, posaconazole, anidulafungin and micafungin. In contrast, the highest rate of non-WT was observed in C. orthopsilosis to itraconazole (4 of 13, 30.8). Conclusions: Although almost all of the tested drugs demonstrated potent activity against C. parapsilosis species complex, it seems that more especially C. orthopsilosis isolates had decreased susceptibility to itraconazole. Further studies are needed to determine how these findings may switch into in vivo efficacy. © 2020 Elsevier Masson SA